Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles
Novo Nordisk A/S NVO reported third-quarter 2025 earnings of 70 cents per American Depositary Receipt (ADR), which missed the Zacks Consensus Estimate of 77 cents. The company had reported earnings of 90 cents per ADR in the year-ago quarter. Revenues of $11.74 billion increased 5% year over year in the Danish kroner (DKK) and 11% at […]
Novo Nordisk Is Seeing Slowing Demand for GLP-1s Wegovy and Ozempic
Eric Thayer / Bloomberg via Getty Images Novo Nordisk lowered its guidance in part due to disappointing demand for Ozempic. Key Takeaways Novo Nordisk cut its outlook as it sees slowing demand for its GLP-1 weight loss and diabetes treatments. Third-quarter profit and revenue was short of analysts’ estimates. U.S.-listed shares of Novo Nordisk (NVO) […]
Can a weight loss and diabetes drug treat long COVID?
Scripps Research announced a new clinical trial Thursday that will assess the effectiveness of using drugs approved for diabetes treatment and weight loss to treat long COVID, the debilitating chronic condition diagnosed in an estimated 20 million Americans and about 400 million people worldwide. Developed to help people with type 2 diabetes control their blood […]
GLP-1 Receptor Agonists for Pharmacologically Induced Weight Gain
This Viewpoint discusses the use of glucagon-like peptide-1 (GLP-1) receptor agonists as a strategy to manage psychotropic-induced weight gain.
Prediction: Novo Nordisk Will Soar by 2026
Novo Nordisk (NYSE: NVO) has dropped over 50%, but its expanding GLP-1 pipeline and bold $5.2 billion acquisition could drive the next phase of explosive growth. With analysts turning bullish, investors might be looking at one of 2025’s biggest comeback stories. Stock prices used were the market prices of Oct. 28, 2025. The video was […]
Novo Nordisk’s Obesity Pill Shows Cardiovascular Benefits, Comparable Efficacy to Injection
Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar control and reduced cardiovascular risk factors,… Reuters Health Information
STAT+: Pharmalittle: We’re reading about a Trump deal with Lilly and Novo, fewer U.S. generic drug plants, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup […]
From falling knife to opportunity: my take on Diageo shares
The Diageo (LSE: DGE) share price has fallen more than 55% since early 2022, while the FTSE 100 has climbed around 35% over the same period. For a long time, I saw the stock as a classic falling knife and stayed well away. But markets often overshoot in both directions. Taking a contrarian stance is […]
Hims & Hers: GLP-1 Partnership Could Unlock Value
De-escalating GLP-1s to Every-2-Weeks Maintenance Option
In a small study, patients who have successfully lost weight with weekly GLP-1 treatment maintain their weight loss and metabolic improvements with every-other-week dosing. Medscape Medical News